Skip to main content
SpringerLink
Log in

OK-432-combined adoptive immunotherapy as a prognostic factor in peritoneal metastasis from gastric cancer

  • Original Articles
  • Published:
Surgery Today Aims and scope Submit manuscript

Abstract

Prognostic factors, such as preoperative status, intraoperative findings, and postoperative treatments, were evaluated in 61 patients with peritoneal metastasis from gastric cancer treated in our facility between 1979 and 1991. Since 1986, 23 patients have been treated with OK-432-combined adoptive immunotherapy (AIT). OK-432-combined AIT is a sequential treatment via a catheter inserted into the abdominal cavity, using a streptococcal preparation, OK-432, followed by the transfer of lymphocytes cultured with T cell growth factor and sonicated tumor extract. A univariate analysis showed that six factors consisting of: (1) age, (2) resection of primary lesion, (3) grade of peritoneal metastasis or serosal invasion, (4) chemotherapy, (5) OK-432, and (6) OK-432-combined AIT influenced survival. The survival of the patients given OK-432-combined AIT (median survival time; MST = 7.5 months) was significantly (P = 0.0267) longer than that of those not receiving OK-432-combined AIT (MST = 4.3 months). A multivariate analysis showed that the most significant factors associated with survival were chemotherapy, resection of the primary lesion, and OK-432-combined AIT. Since these three factors are all therapeutic procedures, the use of combination therapy including OK-432-combined AIT is thus expected to prolong the survival of gastric cancer patients with peritoneal metastasis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Kano T, Kumashiro R, Tamada R, Kodama Y, Inokuchi K (1981) Late results of postoperative long-term cancer chemotherapy for advanced carcinoma of the stomach. Jpn J Surg 11:291–296

    Google Scholar 

  2. Abe R, Akiyoshi T, Baba T (1990) Two-route chemotherapy using cisplatin and its neutralizing agent, sodium thiosulfate, for intraperitoncal cancer. Oncology 47:422–426

    Google Scholar 

  3. Koga S, Hamazoe R, Maeta M, Shimizu N, Murakami A, Wakatsuki T (1988) Prophylactic therapy for peritoneal recurrence of gastric cancer by continuous hyperthermic peritoneal perfusion with mitomycin C. Cancer 61:232–237

    Google Scholar 

  4. Fujimoto S, Shresta RD, Kokubun M, Ohta M, Takahashi M, Kobayashi K, Kiuchi S, Okui K, Miyoshi T, Arimizu N, Takamizawa H (1988) Intraperitoneal hyperthermic perfusion combined with surgery effective for gastric cancer patients with peritoneal seeding. Ann Surg 208:36–41

    Google Scholar 

  5. Torisu M, Katano M, Kimura Y, Itch H, Takesue M (1983) New approach to management of malignant ascites with streptococcal preparation, OK-432. I: Improvement of host immunity and prolongation of survival. Surgery 93:357–364

    Google Scholar 

  6. Tsujitani S, Abe Y, Korenaga D, Saitoh A, Watanabe A, Sugimachi K (1990) Intraperitoneal administration of the biological response modifier OK-432 and peritoneal recurrence following gastrectomy. Hepatogastroenterology 37:498–502

    Google Scholar 

  7. Kan N, Ohgaki K, Inamoto T, Kodama H (1984) Antitumor and therapeutic effects of spleen cells from tumor-bearing mice cultured with T cell growth factor and soluble tumor extract. Cancer Immunol Immunother 18:215–222

    Google Scholar 

  8. Kan N, Okino T, Nakanishi M, Satoh K, Mise K, Yamasaki S, Teramura Y, Ohgaki K, Tobe T (1989) Therapeutic efficacy of sequential therapy with OK-432, cyclophosphamide, IL2-cultured lymphocytes and in vivo IL-2 against advanced murine plasmacytoma. Biotherapy 1:197–206

    Google Scholar 

  9. Hori T, Mise K, Kan N, Okino T, Satoh K, Yamasaki S, Teramura Y, Harada T, Ohgaki K, Kodama H, Tobe T (1992) Therapeutic and life-prolonging effect of intrapleural injection with a streptococcal preparation, OK-432, and IL2-cultured lymphocytes to breast cancer patients with malignant pleural effusion. Biotherapy 5:21–29

    Google Scholar 

  10. Okino T, Kan N, Nakanishi M, Satoh K, Mise K, Teramura Y, Yamasaki S, Hori T, Kodama H, Ohgaki K, Tobe T (1990) The therapeutic effect of OK-432-combined adoptive immunotherapy against liver metastases from breast cancer. J Cancer Res Clin Oncol 116:197–202

    Google Scholar 

  11. Yamasaki S, Okino T, Kan N, Satoh K, Mise K, Teramura Y, Harada T, Kodama H, Hori T, Ohgaki K, Tobe T (1992) Factors influencing the response and survival of the patients with liver metastases from breast cancer receiving OK-432-combined adoptive immunotherapy. J Cancer Res Clin Oncol 118:157–162

    Google Scholar 

  12. Japanese Research Society for Gastric Cancer (1981) The general rules for the gastric cancer study in surgery and pathology. Part I: Clinical classification. Jpn J Surg 11:127–139

    Google Scholar 

  13. Nakanishi M, Kan N, Okino T, Satoh K, Mise K, Teramura Y, Yamasaki S, Ohgaki K, Tobe T (1990) Comparison between crude interleukin-2 and recombinant interleukin-2 in maintaining killing activity of cultured lymphocytes. Biotherapy 2:21–32

    Google Scholar 

  14. Inamoto T, Ohgaki K, Hikasa Y, Kodama H (1984) Specific antitumor immunity in pre- and postoperative state and 5-year survival of breast cancer patients. Arch Jpn Chir 53:345–352

    Google Scholar 

  15. Kan N, Okino T, Kodama H, Ohgaki K, Tobe T, Inamoto T (1987) Breast cancer-specific immunity evaluated by a new in vitro method: IL-2 enhanced MLTR (in Japanese with English abstract). Nippon Geka Gakkai Zasshi (J Jpn Surg Soc) 88:1624–1631

    Google Scholar 

  16. Okino T, Kan N, Mise K, Nakanishi M, Satoh K, Yamasaki S, Teramura Y, Hori T, Inoue K, Ohgaki K, Tobe T (1990) Adoptive immunotherapy against peritoneal metastases from stomach cancer: Application of regional lymph node lymphocytes (in Japanese with English abstract). Nippon Gan Chiryo Gakkai Shi (J Jpn Soc Cancer Ther) 25:613–620

    Google Scholar 

  17. Cox DR (1972) Regression models and life tables. J Roy Star Soc (B) 34:187–220

    Google Scholar 

  18. Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA (1982) Lymphokine-activated killer cell phenomenon: Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med 155:1834–1841

    Google Scholar 

  19. Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT, Seipp CA, Simpson CG, White DE (1987) A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. New Engl J Med 316:889–897

    Google Scholar 

  20. Yamasaki S, Kan N, Mise K, Harada T, Ichinose Y, Morigichi Y. Kodama H. Satoch K, Ohgaki K, Tobe T (1993) Cellular interaction against autologous tumor cells between IL-2-cultured lymphocytes and fresh peripheral blood lymphocytes in patients with breast cancer given immuno-chemotherapy. Biotherapy 6:63–71

    Google Scholar 

  21. Mise K, Kan N, Okino T, Nakanishi M, Satoh K, Teramura Y, Yamasaki S, Ohgaki K, Tobe T (1990) Effect of heat treatment on tumor cells and antitumor effector cells. Cancer Res 50:6199–6202

    Google Scholar 

  22. Iitsuka Y, Shiota S, Matsui T, Murata Y, Kimura A, Koga S (1990) Relationship between the cytologic characteristics of intraperitoneal free cancer cells and the prognosis in patients with gastric cancer. Acta Cytol 34:437–442

    Google Scholar 

  23. Esaki Y, Hirayama R, Hirokawa K (1990) A comparison of the patterns of metastasis in gastric cancer by histologic type and age. Cancer 65:2086–2090

    Google Scholar 

  24. Hahn H, Saito N, Sato Y, Takeshita K, Sunagawa M, Endo M (1990) Results of surgery in patients with gastric cancer extending to the adjacent organs. Hepatogastroenterology 37:417–420

    Google Scholar 

  25. Asao T, Fukuda T, Yazawa S, Nagamachi Y (1991) Carcinoembryonic antigen levels in peritoneal washings can predict peritoneal recurrence after curative resection of gastric cancer. Cancer 68:44–47

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Laboratory of Oncologic Surgery, First Department of Surgery, Kyoto University, Faculty of Medicine, 54 Kawara-cho, Shogoin, 606, Sakyo-ku, Kyoto, Japan

    Keiichi Mise, Norimichi Kan, Takashi Okino, Yoshio Moriguchi, Takehisa Harada, You Ichinose & Kazutomo Inoue

Authors
  1. Keiichi Mise
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Norimichi Kan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Takashi Okino
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yoshio Moriguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Takehisa Harada
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. You Ichinose
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Kazutomo Inoue
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mise, K., Kan, N., Okino, T. et al. OK-432-combined adoptive immunotherapy as a prognostic factor in peritoneal metastasis from gastric cancer. Surg Today 24, 54–58 (1994). https://doi.org/10.1007/BF01676886

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01676886

Key Words

Search

Navigation